VATALANIB
Total Payments
$168,586
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $168,586 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $168,586 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I TRIAL OF THE MTOR INHIBITOR RAD001 IN COMBINATION WITH VEGF RECEPTOR TYROSINE KINASE INHIBITOR PTK787 AND OR ZK 222584 IN PATIENTS WITH ADVANCED SOLID TUMOR | Novartis Pharmaceuticals Corporation | $168,586 | 0 |
Top Doctors Receiving Payments for VATALANIB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, MN | $168,586 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $168,586
Product Information
- Type Drug
- Total Payments $168,586
- Total Doctors 0
- Transactions 1
About VATALANIB
VATALANIB is a drug associated with $168,586 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2017. In 2017, $168,586 was paid across 1 transactions to 0 doctors.
The most common payment nature for VATALANIB is "Unspecified" ($168,586, 100.0% of total).
VATALANIB is associated with 1 research study, including "A PHASE I TRIAL OF THE MTOR INHIBITOR RAD001 IN COMBINATION WITH VEGF RECEPTOR TYROSINE KINASE INHIBITOR PTK787 AND OR ZK 222584 IN PATIENTS WITH ADVANCED SOLID TUMOR" ($168,586).